http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2113699-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa48a431ce250933eb0fdd7a1caf3f30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 |
| filingDate | 1971-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5ea57ddd9ec8fc477c3cdbbe93b5b34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dbb4d957e14d9bf157f0e9c63ba4759e |
| publicationDate | 1971-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-2113699-A1 |
| titleOfInvention | Orally administrable alkali or alkaline earth salt of salicylamide |
| abstract | A dosage unit form suitable for oral administration comprises an alkali(ne earth)metal salt of salicylamide (I) and opt. alkali(ne earth)metal salt of acetominophen (II). (I) is an analgesic, antipyretic and anti-inflammatory agent and the compn. give high blood levels of (I). The ratio of (I):(II) may be 0.25:1 to 40:1. Dosage forms include enteric coated tablets and effervescent compsn. Units doses contain 50-750 mg, esp. 300 mg. (I). |
| priorityDate | 1970-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.